Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian)

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jun 2

PMID 34069845

Citations 15

Authors

Camille Evrard

Jerome Alexandre

Affiliations

Soon will be listed here.

Abstract

For endometrial cancer, a new classification is now available from ESMO, ESGO, and ESTRO based on clinical and molecular characteristics to determine adjuvant therapy. The contribution of molecular biology is major for this pathology mainly by the intermediary of deficient mismatch repair/microsatellite instability. Detection techniques for this phenotype have many peculiarities in gynecologic cancers (endometrial and ovarian) because it has been initially validated in colorectal cancer only. Endometrial cancer is the most common tumor with deficient mismatch repair, which is an important prognostic factor and a predictor of the benefit of adjuvant treatments. Concerning advanced stages, this phenotype is a theragnostic marker for using immunotherapy. Among ovarian cancer, microsatellite instability is less described in literature but exists, particularly in endometrioid type ovarian cancer. This review aims to provide an overview of the publications concerning deficient mismatch repair/microsatellite instability in endometrial and ovarian cancers, detection techniques, and clinical implications of these molecular characteristics.

Citing Articles

Radiomics analysis of multiparametric MRI for preoperative prediction of microsatellite instability status in endometrial cancer: a dual-center study.

Jia Y, Hou L, Zhao J, Ren J, Li D, Li H Front Oncol. 2024; 14:1333020.

PMID: 38347846 PMC: 10860747. DOI: 10.3389/fonc.2024.1333020.

Multi-parametric MRI-based radiomics for preoperative prediction of multiple biological characteristics in endometrial cancer.

Ma C, Zhao Y, Song Q, Meng X, Xu Q, Tian S Front Oncol. 2024; 13:1280022.

PMID: 38188296 PMC: 10768555. DOI: 10.3389/fonc.2023.1280022.

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.

Pawlowska A, Rekowska A, Kurylo W, Panczyszyn A, Kotarski J, Wertel I Int J Mol Sci. 2023; 24(13).

PMID: 37446039 PMC: 10341806. DOI: 10.3390/ijms241310859.

Clear cell endometrial carcinoma with high microsatellite instability in a complicated pregnancy: a case report.

Weiss F, Kaltofen T, Kanitz V, Schroder L, Kost B, Konig A J Med Case Rep. 2023; 17(1):286.

PMID: 37422672 PMC: 10329786. DOI: 10.1186/s13256-023-03994-y.

The Role of FBXW7 in Gynecologic Malignancies.

Di Fiore R, Suleiman S, Drago-Ferrante R, Subbannayya Y, Suleiman S, Vasileva-Slaveva M Cells. 2023; 12(10).

PMID: 37408248 PMC: 10216672. DOI: 10.3390/cells12101415.

References

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks C . Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clin Cancer Res. 2018; 25(8):2537-2548. DOI: 10.1158/1078-0432.CCR-18-3241. View

Kwon J, Scott J, Gilks C, Daniels M, Sun C, Lu K . Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011; 29(16):2247-52. PMC: 4874206. DOI: 10.1200/JCO.2010.32.9979. View

Sepulveda A, Hamilton S, Allegra C, Grody W, Cushman-Vokoun A, Funkhouser W . Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2017; 141(5):625-657. DOI: 10.5858/arpa.2016-0554-CP. View

Kramer P, Talhouk A, Brett M, Chiu D, Cairns E, Scheunhage D . Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin Cancer Res. 2020; 26(20):5400-5410. DOI: 10.1158/1078-0432.CCR-20-1268. View

Wang Y, Shi C, Eisenberg R, Vnencak-Jones C . Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results?. J Mol Diagn. 2016; 19(1):57-64. PMC: 5225298. DOI: 10.1016/j.jmoldx.2016.07.008. View

Murali R, Davidson B, Fadare O, Carlson J, Crum C, Gilks C . High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int J Gynecol Pathol. 2018; 38 Suppl 1:S40-S63. PMC: 6296248. DOI: 10.1097/PGP.0000000000000491. View

Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-57. View

Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9):1067-1074. PMC: 6219495. DOI: 10.1038/s41416-018-0310-8. View

Goodfellow P, Billingsley C, Lankes H, Ali S, Cohn D, Broaddus R . Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol. 2015; 33(36):4301-8. PMC: 4678181. DOI: 10.1200/JCO.2015.63.9518. View

10.

Soliman P, Broaddus R, Schmeler K, Daniels M, Gonzalez D, Slomovitz B . Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?. J Clin Oncol. 2005; 23(36):9344-50. DOI: 10.1200/JCO.2005.03.5915. View

11.

Kobayashi Y, Nakamura K, Nomura H, Banno K, Irie H, Adachi M . Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers. Int J Gynecol Cancer. 2015; 25(3):440-6. DOI: 10.1097/IGC.0000000000000377. View

12.

Rossi L, Le Frere-Belda M, Laurent-Puig P, Buecher B, de Pauw A, Stoppa-Lyonnet D . Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study. Int J Gynecol Cancer. 2017; 27(5):953-960. DOI: 10.1097/IGC.0000000000000985. View

13.

Beinse G, Rance B, Just P, Izac B, Letourneur F, Saidu N . Identification of mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments. Int J Gynecol Cancer. 2020; 30(5):640-647. DOI: 10.1136/ijgc-2019-000871. View

14.

Raffone A, Travaglino A, Cerbone M, Gencarelli A, Mollo A, Insabato L . Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer. Pathol Oncol Res. 2020; 26(3):1417-1427. DOI: 10.1007/s12253-020-00811-5. View

15.

Akbari M, Zhang S, Cragun D, Lee J, Coppola D, Mclaughlin J . Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. Fam Cancer. 2017; 16(3):351-355. DOI: 10.1007/s10689-017-9973-1. View

16.

de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C . Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019; 20(9):1273-1285. PMC: 6722042. DOI: 10.1016/S1470-2045(19)30395-X. View

17.

Lu K, Broaddus R . Gynecologic Cancers in Lynch Syndrome/HNPCC. Fam Cancer. 2005; 4(3):249-54. DOI: 10.1007/s10689-005-1838-3. View

18.

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J . ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2015; 26(1):2-30. PMC: 4679344. DOI: 10.1097/IGC.0000000000000609. View

19.

Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F . Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017; 552(7683):116-120. DOI: 10.1038/nature24673. View

20.

Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D . Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers (Basel). 2019; 11(10). PMC: 6826728. DOI: 10.3390/cancers11101567. View